Altimmune to Present at Wells Fargo Healthcare Conference
Event summary
- Altimmune to participate in Wells Fargo 21st Annual Healthcare Conference on September 10, 2026.
- Fireside chat scheduled for 9:30 a.m. ET, webcast available via Altimmune's website.
- Company focuses on pemvidutide, a dual-action therapy for liver diseases.
- Target indications include MASH, AUD, and ALD.
The big picture
Altimmune's participation in the Wells Fargo Healthcare Conference comes as the biopharmaceutical sector faces increasing competition in liver disease treatments. The company's focus on pemvidutide, targeting both glucagon and GLP-1 receptors, positions it in a niche but growing market. The strategic significance lies in how Altimmune can leverage this platform to attract potential partners or investors amid a crowded field of late-stage clinical candidates.
What we're watching
- Clinical Progress
- How Altimmune's presentation will highlight pemvidutide's development timeline and regulatory strategy.
- Market Positioning
- Whether Altimmune can differentiate pemvidutide in the competitive liver disease therapy space.
- Investor Sentiment
- The impact of the conference presentation on investor confidence and stock performance.